Allergan Inc. (NYSE: AGN) shares closed down 5.39% on Wednesday with about 12 million shares traded after Valeant raised its hostile bid on the company. Valeant added $10 a share in cash to last month's original offer of $48.30 plus 0.83 of a Valeant share for each Allergan share, coming to a total of $49.4 billion.
Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets.
Get more information on Allergan Inc. and free access to the in depth equity report at: www.TrendingWallStreet.com/stockquote/AGN
TrendingWallStreet.com wants to help everyday people gain awareness about some of the hottest penny stocks trading in the stock market today. TrendingWallStreet.com releases momentum alerts on companies that you may have never heard about or thought about looking at. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get full access to our free stock reports.
Apple Inc. (NASDAQ: AAPL) shares sailed to a new 52-week high of $629.83 during intra-day trading on Wednesday. The company announced that it will be buying Beats Electronics LLC for $3 billion. The company will continue to use the Beats brand.
Apple Inc. and its wholly-owned subsidiaries design, manufacture, and market mobile communication and media devices, personal computers, and portable digital music players worldwide. It also sells software, services, peripherals, networking solutions, and third-party digital content and applications related to its products.
Get more information on Apple Inc. and free access to the in depth equity report at” www.TrendingWallStreet.com/stockquote/AAPL
Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.